Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 27, 2023 09:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN FRANCISCO and BERLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that...
June 01, 2023 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting

SAN FRANCISCO and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that...
February 08, 2023 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer

SAN FRANCISCO and BERLIN, Feb. 08, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that...
October 20, 2022 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors TK-8001 targets a MAGE-A1...
April 08, 2022 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting

SAN FRANCISCO, April 08, 2022 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced it is advancing...
January 05, 2022 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel

SAN FRANCISCO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced the appointment...
November 30, 2021 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors

SAN FRANCISCO, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that...
November 15, 2021 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T

- Preclinical, Translational and Clinical Trial Posters for TK-8001 Presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting - Plan to initiate a first-in-human, Phase 1/2...
October 01, 2021 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

SAN FRANCISCO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that three...
August 04, 2021 08:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Appoints Peggy Sotiropoulou, Ph.D. as Chief Scientific Officer

SAN FRANCISCO and BERLIN, Aug. 04, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc. a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for patients with...